Skip directly to content

Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendations

June 2016

By Suraj Madoori
Edited by Erica Lessem and Kenyon Farrow

The End of TB Starts with Science

Eliminating tuberculosis (TB), the leading infectious killer in the world, will not happen without the critical leadership of the United States. Innovative policymaking underpinned by catalyzing science has led to a dramatic reduction in the number of new TB cases each year in the country. Yet TB is still far from global elimination, and an uptick in the number of new domestic TB cases in 2015 points to the fragility of progress.

Zepatier

The goal of hepatitis C virus (HCV) treatment is a cure (when there is no hepatitis C virus in a person’s bloodstream at least 12 weeks after treatment is finished).

What is Zepatier?

Zepatier is two hepatitis C virus-fighting drugs in one tablet. These drugs block different steps of the virus lifecycle. In the United States, Zepatier is approved for people who are over 18 years old with hepatitis C genotype 1 or genotype 4.

How is Zepatier used?

Zepatier is a beige pill, taken once daily, with or without food, for 12 or 16 weeks.

FOR IMMEDIATE RELEASE
Contacts: Mikola De Roo, 347-585-6051, m.deroo@housingworks.org; Anthony Hayes, 646-591-4893, AnthonyH@GMHC.org; Elizabeth Koke, 347-473-7459, e.koke@housingworks.org

AN OPEN LETTER TO SENATOR SANDERS CHALLENGING THE CHARACTERIZATION OF MEETING WITH HIV/AIDS ACTIVISTS

May 27, 2016

Dear Senator Sanders:

We are grateful that you took time to sit with us this week to discuss a broad range of issues related to the fight against HIV/AIDS.

On December 4, 2015, in Cape Town, South Africa, Treatment Action Group, Harvard Medical School, Partners In Health, Treatment Action Campaign, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference in Barcelona.

The symposium, “Scale Up to Get Down to Zero TB Deaths, New Infections, and Suffering,” focused on scaling up active case finding, preventive therapy, and MDR-TB diagnosis and treatment. These interventions are critical to TB elimination but not widely implemented.

U.S. and Global Health Policy Director

Suraj leads TAG’s domestic and global policy work across the HIV, TB, and HCV projects.

Prior to joining TAG, Suraj was associate director of the HIV Prevention Justice Alliance (HIV PJA) and associate director of national/federal policy at the AIDS Foundation of Chicago (AFC). During his tenure at AFC and HIV PJA, Suraj directed the national advocacy campaign work of the 13,000-member HIV PJA community mobilization network and helped push for a significant language change undertaken by the CDC to reflect

Finance Manager

As TAG’s finance manager, David is responsible for the management of TAG's financials, development and maintenance of the budget and internal controls, and collaboration with TAG's external auditor. 

David has extensive experience in not-for-profit financial management. Prior to joining TAG, he was the senior grant accountant/financial analyst at a not-for-profit focused on various aspects of the Lower East Side community. His portfolio focused on education at all stages.

April 16, 2016 – FOR IMMEDIATE RELEASE

Barcelona, Spain – People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of lifesaving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.  

“New direct-acting antivirals (DAAs) cure nearly everyone from hepatitis C—but Gilead’s greed prevents universal access to their lifesaving medicines.

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

TAGline Fall 2016

HEALTH, HUMAN RIGHTS, and SOCIAL JUSTICE

By Tim Horn

Maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs.

TAGline Spring 2016

Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability

By Tracy Swan

TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work exploring what it actually costs to profitably mass-produce generic drugs for HIV, viral hepatitis, and cancer. These estimates are based on the molecular structure, complexity, dose, and duration of treatment with each drug.

Achieving these prices—between $200 and $400 for a

TAGline Spring 2016

A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them

By James Krellenstein and Jeremiah Johnson

On July 16, 2012, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’ Truvada (co-formulated tenofovir disoproxil fumarate and emtricitabine) for HIV pre-exposure prophylaxis (PrEP). The approval of Truvada is a historic advance for HIV prevention efforts.

Pages